Britannia Q3 Results Preview: The company is seen reporting a moderate 1.2% year-on-year (YoY) growth in consolidated revenue for the December quarter due to flat growth in volumes, according to the average of estimates given by 10 brokerage firms.
Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in Brazil
Biocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis received full allocation under the